Clinical Trial Update: Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

View source ↗

Summary

Clinical trial update indicates the study comparing Buphenyl to Ravicti for Byler disease is no longer available, effectively ending the transition trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Byler Disease
• Progressive Familial Intrahepatic Cholestasis Type

Drugs mentioned

• BUPHENYL (Sodium phenylbutyrate)
• Ravicti (glycerol phenylbutyrate)

Snippet

Sponsor: University of Pittsburgh | Conditions: Byler Disease | Status: NO_LONGER_AVAILABLE